Labetalol HCl
Labetalol HCl is a selective antagonist for the α1-adrenergic receptor and a non-selective antagonist for the β-adrenergic receptor. Labetalol HCl has been used for the treatment of high blood pressure. Labetalol HCl competitively targets the α1-adrenergic receptors expressed in vascular smooth muscle, thus inhibiting adrenergic stimulation on endothelial cells and vasoconstriction in peripheral blood vessels. Labetalol HCl also blocks the β-adrenergic receptors in bronchial and vascular smooth muscle to counteract adrenergic stimulation. Ultimately, labetalol HCl causes decreases in resting and exercise heart rates, cardiac output, as well as in both systolic and diastolic blood pressure, exherting vasodilation, as well as negative chronotropic and inotropic cardiac effects.?
References:
1.?National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 3869, Labetalol. Retrieved August 21, 2021.
2. Dage RC, Hsieh CP. Direct vasodilatation by labetalol in anaesthetized dogs. British Journal of Pharmacology, 1980, 70(2): 287-293.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 364.87 |
| Cas No. | 32780-64-6 |
| Formula | C19H25ClN2O3 |
| Solubility | insoluble in H2O; ≥18.24 mg/mL in DMSO; ≥2.98 mg/mL in EtOH with gentle warming and ultrasonic |
| Chemical Name | 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide;hydrochloride |
| SDF | Download SDF |
| Canonical SMILES | CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O.Cl |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Animal experiment:[2] | |
|
Animal models |
Anaesthetized dogs |
|
Dosage form |
0.03 ~ 1 mg/kg Given intravenously and into the vertebral artery |
|
Applications |
Labetalol HCl did not cause any immediate (5 min) change in blood pressure or heart rate when given by either route. When the cumulative dose of labetalol HCl reached 2.86 mg/kg, blood pressure fell significantly. In addition, intravenous administration of 0.03 mg/kg labetalol HCl was enough to increase heart rate at its first dose. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 3869, Labetalol. Retrieved August 21, 2021. 2. Dage RC, Hsieh CP. Direct vasodilatation by labetalol in anaesthetized dogs. British Journal of Pharmacology, 1980, 70(2): 287-293. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
